GenesisCare renews RadCalc QA software in 173 radiation oncology centers to offer patient access to more precise, targeted therapy

RadCalc is a leading dosimetric verification software.
(PresseBox) ( Lüneburg, )
LAP is today announcing it has strengthened its partnership with leading integrated oncology care provider, GenesisCare, to continue providing advanced treatment planning software in radiation oncology centres around the globe.

As the complexity of treatment planning in radiation oncology increases, it is imperative for physicians and radiation therapists to have confidence in the accuracy of secondary dose verification. RadCalc’s independent 3D calculations has allowed GenesisCare and other providers a more accurate analysis of the dose being delivered to their patients with customizable automation designed to fit any clinical workflow.

GenesisCare will continue to employ RadCalc in 173 radiation oncology sites across Australia, the United Kingdom, Spain and the United States, with room for further expansion to other sites in the future.  Included in the agreement is also RadCalc’s 3D premium for the UK region and GammaKnife solution.

GenesisCare is the world’s largest provider of radiotherapy – an important treatment option for cancer patients – and provides patients with access to diagnostics, medical oncology, surgical oncology, radiotherapy, and novel therapies alongside the ability to participate in the latest clinical trials.

“RadCalc is a comprehensive treatment plan analysis tool that ensures our patients receive the highest quality precision care and treatment plans that have the best chance of improving patient outcomes,” said Tim Fox, GenesisCare’s Global Head of Medical Physics and Clinical Technology.

With their collaboration both parties aim to enhance safety and efficiency in radiation oncology.
The publisher indicated in each case is solely responsible for the press releases above, the event or job offer displayed, and the image and sound material used (see company info when clicking on image/message title or company info right column). As a rule, the publisher is also the author of the press releases and the attached image, sound and information material.
The use of information published here for personal information and editorial processing is generally free of charge. Please clarify any copyright issues with the stated publisher before further use. In the event of publication, please send a specimen copy to